Home » General World News » ‘We’re not going to follow the hype’: Biotech VCs are concerned by the staggering size of early-stage startup funding

‘We’re not going to follow the hype’: Biotech VCs are concerned by the staggering size of early-stage startup funding





Biotech pharma lab drug development

  • Money is flowing into biotech startups, with companies more and more frequently raising more than $100 million in early-stage funding rounds.
  • We asked venture capitalists what all this capital meant for the private biotech industry.
  • Some were excited for the science while concerned about the expectations that come along with this greater funding, but others are finding ways to look past the hype.

Over the past few years, biotech startups have been successful at raising large amounts of capital just as they’re starting out. It has led to a lot of unicorns, with multibillion-dollar-valued companies having raised hundreds of millions in their read more >>>

Source:: BusinessInsider.Com

Comments are closed.